lamivudine-hbv - oral, Epivir HBV
GENERIC NAME: LAMIVUDINE-HBV - ORAL (la-MIV-ue-deen)
BRAND NAME(S): Epivir HBV
WARNING: Lactic acid buildup in the blood (lactic acidosis) and sometimes fatal liver disease have occurred with the use of lamivudine-HBV, used both alone and in combination with other drugs for treating human immunodeficiency virus (HIV) infection.
HIV counseling and testing should be offered to all patients both before and during treatment with lamivudine-HBV. Lamivudine-HBV contains a lower dose of the drug lamivudine, which is used to treat HIV infection as well as hepatitis B. Use of lamivudine-HBV in patients with unknown or untreated HIV infection could result in new types of HIV virus that are more difficult to treat (drug-resistant).
Severe worsening of hepatitis has occurred when this medication is stopped. Liver and blood testing should continue for several months after lamivudine-HBV is stopped. Consult your doctor or pharmacist for more information.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index